Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2184
Wed, 09.11.2022
Epigenomics AG
Epigenomics AG reports financial results for the first nine months 2022
Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022.
Key figures
Total revenue decreased to EUR 386 thousand in 9M 2022, [ … ]
Wed, 09.11.2022
Epigenomics AG
Epigenomics AG reports financial results for the first nine months 2022
Berlin (Germany) and San Diego, CA (U.S.A.), November 9, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2022.
Key figures
Total revenue decreased to EUR 386 thousand in 9M 2022, [ … ]
Mon, 19.09.2022
Epigenomics AG
Publication of inside information pursuant to Article 17 MAR
Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs
Berlin, September 19, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") raises its earnings guidance for the c [ … ]
Mon, 19.09.2022
Epigenomics AG
Publication of inside information pursuant to Article 17 MAR
Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs
Berlin, September 19, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") raises its earnings guidance for the c [ … ]
Mon, 19.09.2022
Epigenomics AG
Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test
First subject has been enrolled in the Company’s CRC-DRAW trial
Data to be used as basis for planned PMA submission to FDA
Berlin (Germany) and San Diego, CA (U.S.A.), September 19, 2022 - Epigenomics Inc, a wholly-owned subsidia [ … ]
Mon, 19.09.2022
Epigenomics AG
Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test
First subject has been enrolled in the Company’s CRC-DRAW trial
Data to be used as basis for planned PMA submission to FDA
Berlin (Germany) and San Diego, CA (U.S.A.), September 19, 2022 - Epigenomics Inc, a wholly-owned subsidia [ … ]
Fri, 09.09.2022
Epigenomics AG
Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
Berlin, September 9, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") plans to propose to the extraordinary Shareholders' Meeting, which is to be convened on October 21, 2022 and conducted as a virtual general meeting without physical presence of [ … ]
Fri, 09.09.2022
Epigenomics AG
Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
Berlin, September 9, 2022 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") plans to propose to the extraordinary Shareholders' Meeting, which is to be convened on October 21, 2022 and conducted as a virtual general meeting without physical presence of [ … ]
Mon, 15.08.2022
Epigenomics AG
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
Berlin, August 15, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the Company has been incurred. This anticipated [ … ]
Mon, 15.08.2022
Epigenomics AG
Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktG
Berlin, August 15, 2022 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the Company has been incurred. This anticipated [ … ]